Aurinia Pharmaceuticals Inc. provided revenue guidance for the fiscal year 2024. for the year, the company expects net product revenue guidance of $200 million- $220 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.02 USD | -2.90% | -1.57% | -44.16% |
05-07 | Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value | CI |
05-02 | Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.16% | 738M | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024